Search research articles
Contact Us
Filters
Showing results (201-210 of 225) with videos related to
Page
of 23
Sort By:
The Journal of Infection
|
April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines
Robert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
The Journal of Infectious Diseases
|
February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01
Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
The Lancet. Child & Adolescent Health
|
September 1, 2018
Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons
Carine Claeys, Khalequ Zaman, Ghassan Dbaibo, et al.
The Journal of Infectious Diseases
|
July 21, 2023
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial
Xavier Sáez-Llorens, Ximena Norero, Marisa Márcia Mussi-Pinhata, et al.
JCI Insight
|
November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions
Ruth O Payne, Sarah E Silk, Sean C Elias, et al.
Lancet (London, England)
|
December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Arabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
The Journal of Infection
|
August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial
Leila Janani, Alasdair P S Munro, Annie Wright, et al.
The Lancet. Infectious Diseases
|
May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
Alasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)
|
December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
Med (New York, N.Y.)
|
July 5, 2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
Angela M Minassian, Sarah E Silk, Jordan R Barrett, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 225) with videos related to
Sort By:
Page
of 23
The Journal of Infection
|
April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines
Robert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
The Journal of Infectious Diseases
|
February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01
Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
The Lancet. Child & Adolescent Health
|
September 1, 2018
Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons
Carine Claeys, Khalequ Zaman, Ghassan Dbaibo, et al.
The Journal of Infectious Diseases
|
July 21, 2023
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial
Xavier Sáez-Llorens, Ximena Norero, Marisa Márcia Mussi-Pinhata, et al.
JCI Insight
|
November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions
Ruth O Payne, Sarah E Silk, Sean C Elias, et al.
Lancet (London, England)
|
December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Arabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
The Journal of Infection
|
August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial
Leila Janani, Alasdair P S Munro, Annie Wright, et al.
The Lancet. Infectious Diseases
|
May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
Alasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)
|
December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
Med (New York, N.Y.)
|
July 5, 2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
Angela M Minassian, Sarah E Silk, Jordan R Barrett, et al.
Page
of 23